{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:55:30Z","timestamp":1789055730844,"version":"build-2803163510"},"reference-count":172,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2005500"],"award-info":[{"award-number":["2020YFC2005500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The emergence of COVID-19 has been associated with an increased risk of arteriovenous thrombosis, with immune inflammation playing a significant role in the pathogenesis of thrombosis. Numerous drug-related clinical trials have been undertaken to prevent thrombosis, and guidelines for its prevention and treatment are continuously evolving as our understanding of the disease progresses. This article provides a comprehensive review of the mechanisms underlying thrombosis in COVID-19 patients, as well as the advancements in clinical trials and guidelines for thrombosis prevention with pharmacological interventions.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1593885","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:33:27Z","timestamp":1754026407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["COVID-19: a vascular nightmare\u00a0unfolding"],"prefix":"10.3389","volume":"16","author":[{"given":"Qinan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2023.03.002","article-title":"Long COVID: pathophysiological factors and abnormalities of coagulation","volume":"34","author":"Turner","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41401-022-00998-0","article-title":"Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies","volume":"44","author":"Xu","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25982","article-title":"Thrombosis in COVID-19","volume":"95","author":"Hanff","year":"2020","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.33963\/KP.a2021.0154","article-title":"COVID-19 and thrombosis: Clinical features, mechanism of disease, and therapeutic implications","volume":"79","author":"Violi","year":"2021","journal-title":"Kardiol Pol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2022.03.001","article-title":"The cardiovascular manifestations of COVID-19","volume":"40","author":"Louis","year":"2022","journal-title":"Cardiol Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemostasis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12879-024-09374-1","article-title":"A systematic review of thromboembolic complications and outcomes in hospitalised COVID-19 patients","volume":"24","author":"Othman","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18502\/jthc.v18i3.14110","article-title":"Prevalence of thromboembolic events, including venous thromboembolism and arterial thrombosis, in patients with COVID-19: A systematic review with meta-analysis","volume":"18","author":"Bagheri","year":"2023","journal-title":"J Tehran Heart Cent"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-022-02766-7","article-title":"Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis","volume":"55","author":"Zuin","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00223-7","article-title":"Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study","volume":"22","author":"Burn","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1186\/s12889-024-19264-5","article-title":"Post-COVID syndrome prevalence: a systematic review and meta-analysis","volume":"24","author":"Sk Abd Razak","year":"2024","journal-title":"BMC Public Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102659","DOI":"10.1016\/j.eclinm.2024.102659","article-title":"Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study","volume":"73","author":"Jara-Palomares","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0040-1718888","article-title":"The clotting trigger is an important determinant for the coagulation pathway in vivo or in vitro-inference from data review","volume":"47","author":"He","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"B15","doi-asserted-by":"publisher","first-page":"154880","DOI":"10.1016\/j.phymed.2023.154880","article-title":"Potential anticoagulant of traditional chinese medicine and novel targets for anticoagulant drugs","volume":"116","author":"Yin","year":"2023","journal-title":"Phytomedicine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30216-7","article-title":"Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study","volume":"7","author":"Goshua","year":"2020","journal-title":"Lancet Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-021-09805-6","article-title":"COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects","volume":"24","author":"Smadja","year":"2021","journal-title":"Angiogenesis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.122.318721","article-title":"Monocyte-mediated thrombosis linked to circulating tissue factor and immune paralysis in COVID-19","volume":"44","author":"Goonewardena","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12933-023-02097-8","article-title":"Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus","volume":"23","author":"Valencia","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2022.76.62-65","article-title":"Multi-factorial mechanism behind COVID-19 related thrombosis","volume":"76","author":"Ali","year":"2022","journal-title":"Med Arch"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100117","DOI":"10.1016\/j.tru.2022.100117","article-title":"The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges","volume":"8","author":"Ma","year":"2022","journal-title":"Thromb Update"},{"key":"B25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.yjmcc.2021.11.010","article-title":"Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications","volume":"164","author":"Ma","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1\u20137 axis of the renin\u2013angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circulation research"},{"key":"B27","article-title":"Prothrombotic effects of angiotensin","volume":"45","author":"Brown","year":"2000","journal-title":"Advances in Internal Medicine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100110","DOI":"10.1016\/j.tru.2022.100110","article-title":"The mechanistic basis linking cytokine storm to thrombosis in COVID-19","volume":"8","author":"Wolf","year":"2022","journal-title":"Thromb Update"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00536-9","article-title":"Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19","volume":"21","author":"Bonaventura","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2174\/0115665240258746230919165935","article-title":"The role of tissue factor in signaling pathways of pathological conditions and angiogenesis","volume":"24","author":"Heidari","year":"2023","journal-title":"Curr Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.123.320144","article-title":"Tissue factor and COVID-19 associated thrombosis","volume":"44","author":"Mackman","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/00033197231153204","article-title":"Vascular \u201cLong COVID\u201d: A new vessel disease","volume":"75","author":"Zanini","year":"2024","journal-title":"Angiology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tim.2023.06.004","article-title":"SARS-CoV-2 and the spike protein in endotheliopathy","volume":"32","author":"Perico","year":"2024","journal-title":"Trends Microbiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2016.11.007","article-title":"Coagulation and sepsis","volume":"149","author":"Levi","year":"2017","journal-title":"Thromb Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13613-019-0499-6","article-title":"Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study","volume":"9","author":"Schmitt","year":"2019","journal-title":"Ann Intensive Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04138-8","article-title":"COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure","volume":"99","author":"Marchetti","year":"2020","journal-title":"Ann Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01823-y","article-title":"Serum from COVID-19 patients promotes endothelial cell dysfunction through protease-activated receptor 2","volume":"73","author":"Vieceli Dalla Sega","year":"2024","journal-title":"Inflammation Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13569","article-title":"Anticoagulant therapy in COVID-19: A narrative review","volume":"16","author":"Mohseni Afshar","year":"2023","journal-title":"Clin Transl Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg7942","article-title":"Persistent complement dysregulation with signs of thromboinflammation in active Long Covid","volume":"383","author":"Cervia-Hasler","year":"2024","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.02.016","article-title":"COVID-19 and thrombosis: The role of hemodynamics","volume":"212","author":"Sastry","year":"2022","journal-title":"Thromb Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2021.0704","article-title":"Coagulation disorders and thrombosis in COVID-19 patients and a possible mechanism involving endothelial cells: A review","volume":"13","author":"Chen","year":"2022","journal-title":"Aging Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.04.039","article-title":"Thromboinflammation in long COVID-the elusive key to postinfection sequelae","volume":"21","author":"Nicolai","year":"2023","journal-title":"J Thromb Haemost"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15830","article-title":"Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction","volume":"20","author":"Fogarty","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.apsb.2012.12.007","article-title":"Hypoxia, vascular smooth muscles and endothelium","volume":"3","author":"Chan","year":"2013","journal-title":"Acta Pharm Sin B"},{"key":"B45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.thromres.2019.07.013","article-title":"The stimulation of thrombosis by hypoxia","volume":"181","author":"Gupta","year":"2019","journal-title":"Thromb Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12967-020-02305-z","article-title":"Hypoxia-induced complement dysregulation is associated with microvascular impairments in mouse tracheal transplants","volume":"18","author":"Khan","year":"2020","journal-title":"J Transl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218479","article-title":"Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study","volume":"79","author":"Ramiro","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3928\/1542-8877-19910101-16","article-title":"Intravitreal suture: a complication of pterygium surgery","volume":"22","author":"Solomon","year":"1991","journal-title":"Ophthalmic Surg"},{"key":"B49","doi-asserted-by":"publisher","first-page":"173644","DOI":"10.1016\/j.ejphar.2020.173644","article-title":"Treatment for COVID-19: an overview","volume":"889","author":"Stasi","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1915129","article-title":"Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management","volume":"19","author":"Savla","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252011267","article-title":"Immunity and coagulation in COVID-19","volume":"25","author":"Avdonin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment","volume":"39","author":"Soy","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2174\/1389450124666221025102929","article-title":"COVID-19 induces cytokine storm and dysfunctional hemostasis","volume":"23","author":"Charles","year":"2022","journal-title":"Curr Drug Targets"},{"key":"B54","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38067","article-title":"Common coagulopathies associated with COVID-19 patients","volume":"15","author":"Gupta","year":"2023","journal-title":"Cureus"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612782","article-title":"The management of COVID-19-related coagulopathy: A focus on the challenges of metabolic and vascular diseases","volume":"24","author":"Szilveszter","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/v15040938","article-title":"Inflammatory response and activation of coagulation after COVID-19 infection","volume":"15","author":"Teodoro","year":"2023","journal-title":"Viruses"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad084","article-title":"NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis","volume":"119","author":"Potere","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000724","article-title":"Complement contributions to COVID-19","volume":"29","author":"Conway","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1832919","article-title":"From COVID-19 to clot: the involvement of the complement system","volume":"40","author":"Hendaus","year":"2022","journal-title":"J Biomol Struct Dyn"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.19429","article-title":"Intrinsic factors behind long COVID: exploring the role of nucleocapsid protein in thrombosis","volume":"13","author":"Eltayeb","year":"2025","journal-title":"PeerJ"},{"key":"B62","doi-asserted-by":"publisher","first-page":"154519","DOI":"10.1016\/j.prp.2023.154519","article-title":"Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients","volume":"247","author":"Ge","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B63","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5493\/wjem.v12.i4.53","article-title":"Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review","volume":"12","author":"Gianni","year":"2022","journal-title":"World J Exp Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008248","article-title":"Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1457324","article-title":"Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective","volume":"15","author":"Murad","year":"2024","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn1077","article-title":"Immune damage in long covid","volume":"383","author":"Ruf","year":"2024","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250010","article-title":"Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis","volume":"53","author":"Cesta","year":"2023","journal-title":"Eur J Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-021-00665-1","article-title":"The state of complement in COVID-19","volume":"22","author":"Afzali","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.22034\/iji.2023.97585.2522","article-title":"Implications of complement imbalance in COVID-19: A molecular mechanistic discussion on the importance of complement balance","volume":"3","author":"Torabizadeh","year":"2023","journal-title":"Iran J Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-020712-164023","article-title":"The multifaceted functions of neutrophils","volume":"9","author":"Mayadas","year":"2014","journal-title":"Annu Rev Pathology: Mech Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/v16111677","article-title":"The contribution of neutrophil extracellular traps to coagulopathy in patients with COVID-19-related thrombosis","volume":"16","author":"Enochs","year":"2024","journal-title":"Viruses"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29887","article-title":"Inflammation-, immunothrombosis,- and autoimmune-feedback loops may lead to persistent neutrophil self-stimulation in long COVID","volume":"96","author":"Thierry","year":"2024","journal-title":"J Med Virol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1507167","article-title":"Neutrophil extracellular traps and macrophage activation contibute to thrombosis and post-covid syndrome in SARS-CoV-2 infection","volume":"16","author":"Serrano-Gonzalo","year":"2025","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e16351","DOI":"10.15252\/emmm.202216351","article-title":"Inhibition of SARS-coV-2-mediated thromboinflammation by CLEC2.Fc","volume":"15","author":"Sung","year":"2023","journal-title":"EMBO Mol Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s00018-024-05157-8","article-title":"Emerging role of complement in COVID-19 and other respiratory virus diseases","volume":"81","author":"Xiao","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073983","article-title":"Neutrophil extracellular traps in cardiovascular and aortic disease: A narrative review on molecular mechanisms and therapeutic targeting","volume":"25","author":"Ibrahim","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150862","article-title":"Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19","volume":"6","author":"Kaiser","year":"2021","journal-title":"JCI Insight"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12985-023-02116-w","article-title":"Neutrophils in COVID-19: recent insights and advances","volume":"20","author":"Li","year":"2023","journal-title":"Virol J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05234-1","article-title":"Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement","volume":"102","author":"Sayyadi","year":"2023","journal-title":"Ann Hematol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.321930","article-title":"Platelets and SARS-coV-2 during COVID-19: immunity, thrombosis, and beyond","volume":"132","author":"Sciaudone","year":"2023","journal-title":"Circ Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.48101\/ujms.v129.9863","article-title":"COVID-19: Not a thrombotic disease but a thromboinflammatory disease","volume":"129","author":"He","year":"2024","journal-title":"Ups J Med Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315175","article-title":"Platelets promote thromboinflammation in SARS-coV-2 pneumonia","volume":"40","author":"Taus","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19159","article-title":"Post-COVID-19 thrombotic sequelae: The potential role of persistent platelet hyperactivity","volume":"204","author":"Schieppati","year":"2024","journal-title":"Br J Haematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19125","article-title":"Prolonged platelet hyperactivity after COVID-19 infection","volume":"204","author":"Nara","year":"2024","journal-title":"Br J Haematol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"11170","DOI":"10.3390\/ijms222011170","article-title":"Inflammatory mediators of platelet activation: focus on atherosclerosis and COVID-19","volume":"22","author":"Theofilis","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001109","article-title":"COVID-19 induces a hyperactive phenotype in circulating platelets","volume":"19","author":"Comer","year":"2021","journal-title":"PloS Biol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14005","article-title":"PDK1 governs thromboxane generation and thrombosis in platelets by regulating activation of Raf1 in the MAPK pathway","volume":"16","author":"Manne","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15275","article-title":"Antibody-mediated platelet activation in COVID-19: A coincidence or a new mechanism of the dysregulated coagulation system","volume":"19","author":"Althaus","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807934","article-title":"The COVID complex: A review of platelet activation and immune complexes in COVID-19","volume":"13","author":"Jevtic","year":"2022","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"118100","DOI":"10.1016\/j.biopha.2025.118100","article-title":"SARS-CoV-2 S1 protein induces IgG-mediated platelet activation and is prevented by 1.8-cineole","volume":"187","author":"Petry","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2021.1912315","article-title":"A double-edged sword: antibody-mediated procoagulant platelets in COVID-19","volume":"32","author":"Millington-Burgess","year":"2021","journal-title":"Platelets"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008762","article-title":"Antibody-induced procoagulant platelets in severe COVID-19 infection","volume":"137","author":"Althaus","year":"2021","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15587","article-title":"Antibody-mediated procoagulant platelet formation in COVID-19 is AKT dependent","volume":"20","author":"Pelzl","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02544-x","article-title":"COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles","volume":"52","author":"Becker","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031920","article-title":"Extracellular vesicles: new players in the mechanisms of sepsis- and COVID-19-related thromboinflammation","volume":"24","author":"Schiavello","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00764-24","article-title":"Circulating extracellular vesicles from severe COVID-19 patients induce lung inflammation","volume":"9","author":"Qian","year":"2024","journal-title":"mSphere"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315547","article-title":"Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality\u2014Brief report","volume":"41","author":"Rosell","year":"2021","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003308","article-title":"Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19","volume":"5","author":"Guervilly","year":"2021","journal-title":"Blood Adv"},{"key":"B100","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1038\/s41598-017-03262-2","article-title":"Different potential of extracellular vesicles to support thrombin generation: contributions of phosphatidylserine, tissue factor, and cellular origin","volume":"7","author":"Tripisciano","year":"2017","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1038\/s41598-024-56841-5","article-title":"The fluorochrome-to-protein ratio is crucial for the flow cytometric detection of tissue factor on extracellular vesicles","volume":"14","author":"Weiss","year":"2024","journal-title":"Sci Rep"},{"key":"B102","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/cells10010085","article-title":"Circulating platelet-derived extracellular vesicles are a hallmark of sars-cov-2 infection","volume":"10","author":"Cappellano","year":"2021","journal-title":"Circulation"},{"key":"B103","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s13054-020-03060-9","article-title":"War to the knife\u201d against thromboinflammation to protect endothelial function of COVID-19 patients","volume":"24","author":"Guglielmetti","year":"2020","journal-title":"Crit Care"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.02.013","article-title":"Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned","volume":"22","author":"Iba","year":"2024","journal-title":"J Thromb Haemost"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-056726","article-title":"Enoxaparin thromboprophylaxis in children hospitalized for COVID-19: A phase 2 trial","volume":"150","author":"Sochet","year":"2022","journal-title":"Pediatrics"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.122.318748","article-title":"Novel tissue factor inhibition for thromboprophylaxis in COVID-19: primary results of the ASPEN-COVID-19 trial","volume":"43","author":"Hess","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.02.041","article-title":"Randomized trial of anticoagulation strategies for noncritically ill patients hospitalized with COVID-19","volume":"81","author":"Stone","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"key":"B109","doi-asserted-by":"publisher","first-page":"n2400","DOI":"10.1136\/bmj.n2400","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"Bmj"},{"key":"B110","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19","volume":"385","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with covid-19","volume":"385","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061533","article-title":"Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT","volume":"146","author":"Bohula","year":"2022","journal-title":"Circulation"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.09.026","article-title":"Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)","volume":"196","author":"Lemos","year":"2020","journal-title":"Thromb Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15450","article-title":"Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial","volume":"19","author":"Perepu","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1055\/a-1485-2372","article-title":"Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial","volume":"122","author":"Bikdeli","year":"2022","journal-title":"Thromb Haemost"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.10.021","article-title":"Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial","volume":"221","author":"Voci","year":"2023","journal-title":"Thromb Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00175-2","article-title":"Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"9","author":"Barco","year":"2022","journal-title":"Lancet Haematol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.11.019","article-title":"Effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19: A systematic review and meta-analysis","volume":"221","author":"Dai","year":"2023","journal-title":"Thromb Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.4266\/acc.2022.01424","article-title":"Comparison of safety and efficacy between therapeutic or intermediate versus prophylactic anticoagulation for thrombosis in COVID-19 patients: a systematic review and meta-analysis","volume":"38","author":"Lee","year":"2023","journal-title":"Acute Crit Care"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-022-03159-7","article-title":"Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis","volume":"18","author":"Vedovati","year":"2023","journal-title":"Intern Emerg Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11239-022-02643-3","article-title":"Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum","volume":"54","author":"Barnes","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.02.011","article-title":"2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19","volume":"22","author":"Schulman","year":"2024","journal-title":"J Thromb Haemost"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20210112-00090","article-title":"Guidelines for diagnosis, prevention and treatment of COVID-19 in adults in China","volume":"18","year":"2021","journal-title":"Chin Med J"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003763","article-title":"American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19","volume":"5","author":"Cuker","year":"2021","journal-title":"Blood Adv"},{"key":"B126","volume-title":"Final coronavirus disease (COVID-19) treatment guidelines","year":"2024"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.02.006","article-title":"Thromboprophylaxis in patients with COVID-19: A brief update to the CHEST guideline and expert panel report","volume":"162","author":"Moores","year":"2022","journal-title":"Chest"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.05.559","article-title":"Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report","volume":"158","author":"Moores","year":"2020","journal-title":"Chest"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-2023-01-20-00115","article-title":"Practice guidelines of thromboprophylaxis and management of anticoagulation in hospitalized patients with COVID-19","volume":"103","year":"2023","journal-title":"Chin Med J"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01214-4","article-title":"Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study","volume":"400","author":"Ballering","year":"2022","journal-title":"Lancet"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01136-X","article-title":"Long COVID: a clinical update","volume":"404","author":"Greenhalgh","year":"2024","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Xie","year":"2022","journal-title":"Nat Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"A clinical case definition of post-COVID-19 condition by a Delphi consensus","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","volume":"116","author":"Guzik","year":"2020","journal-title":"Cardiovasc Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.838011","article-title":"NETosis and neutrophil extracellular traps in COVID-19: immunothrombosis and beyond","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104562","article-title":"Persistent monocytic bioenergetic impairment and mitochondrial DNA damage in PASC patients with cardiovascular complications","volume":"26","author":"Semo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.002","article-title":"Mitochondria in the regulation of innate and adaptive immunity","volume":"42","author":"Weinberg","year":"2015","journal-title":"Immunity"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00426.2020","article-title":"Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19","volume":"320","author":"Ajaz","year":"2021","journal-title":"American Journal of Physiology-cell Physiology"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2014.05.019","article-title":"Mitochondria in monocytes and macrophages-implications for translational and basic research","volume":"53","author":"Ravi","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.04.019","article-title":"Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-coV) infection","volume":"51","author":"Delgado-Roche","year":"2020","journal-title":"Arch Med Res"},{"key":"B141","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/antiox9100936","article-title":"Oxidative stress and inflammation in COVID-19-associated sepsis: the potential role of anti-oxidant therapy in avoiding disease progression","volume":"9","author":"Beltr\u00e1n-Garc\u00eda","year":"2020","journal-title":"Antioxidants"},{"key":"B142","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/idr17010015","article-title":"Genetics of long COVID: exploring the molecular drivers of persistent pulmonary vascular disease symptoms","volume":"17","author":"Ayyoub","year":"2025","journal-title":"Infect Dis Rep"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296668","article-title":"Thrombophilia genetic mutations and their relation to disease severity among patients with COVID-19","volume":"19","author":"Moness","year":"2024","journal-title":"PloS One"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08529.x","article-title":"Risk of cardiovascular disease in double heterozygous carriers and homozygous carriers of F5 R506Q (factor V Leiden) and F2 (prothrombin) G20210A: a retrospective family cohort study","volume":"153","author":"Roach","year":"2011","journal-title":"British Journal of Haematology"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2022.0141","article-title":"Preliminary guidelines for the clinical evaluation and management of long COVID","volume":"54","author":"Kim","year":"2022","journal-title":"Infect Chemother"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2024.0024","article-title":"Updated clinical practice guidelines for the diagnosis and management of long COVID","volume":"56","author":"Seo","year":"2024","journal-title":"Infect Chemother"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8526","article-title":"COVID-19 vaccination and estimated public health impact in california","volume":"5","author":"Tan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7018e1","article-title":"Effectiveness of pfizer-bioNTech and moderna vaccines against COVID-19 among hospitalized adults aged \u226565 years - United States, january-march 2021","volume":"70","author":"Tenforde","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1727284","article-title":"Venous thromboembolism in patients discharged after COVID-19 hospitalization","volume":"47","author":"Engelen","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13063-021-05076-0","article-title":"Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial","volume":"22","author":"Sholzberg","year":"2021","journal-title":"Trials"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15725","article-title":"Risk of venous thromboembolism after COVID-19 vaccination","volume":"20","author":"Houghton","year":"2022","journal-title":"Journal of Thrombosis And Haemostasis"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15751","article-title":"Refractory immune TTP following Pfizer-BioNTech COVID-19 vaccine successfully salvaged with caplacizumab","volume":"20","author":"Laverdure","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-coV-2 vaccine-induced immune thrombotic thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet"},{"key":"B159","doi-asserted-by":"publisher","first-page":"2375269","DOI":"10.1080\/20523211.2024.2375269","article-title":"Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis","volume":"17","author":"Kang","year":"2024","journal-title":"J Pharm Policy Pract"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0488","article-title":"VITT, COVID-19 and the Expert Haematology Panel: The story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme","volume":"21","author":"Chevassut","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"B162","doi-asserted-by":"publisher","first-page":"100884","DOI":"10.1016\/j.rmcr.2019.100884","article-title":"Acute thrombotic vascular events complicating influenza-associated pneumonia","volume":"28","author":"Ishiguro","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/v14122817","article-title":"Thromboembolic events in patients with influenza: A scoping review","volume":"14","author":"Rubino","year":"2022","journal-title":"Viruses"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7403.1358","article-title":"Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis","volume":"326","author":"Wong","year":"2003","journal-title":"Bmj-british Medical Journal"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.10.075","article-title":"Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19","volume":"231","author":"Smilowitz","year":"2021","journal-title":"Am Heart J"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2022.0029","article-title":"Comparing the cytokine storms of COVID-19 and pandemic influenza","volume":"42","author":"Pacheco-Hern\u00e1ndez","year":"2022","journal-title":"J Interferon Cytokine Res"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15509","article-title":"Tissue factor expression, extracellular vesicles, and thrombosis after infection with the respiratory viruses influenza A virus and coronavirus","volume":"19","author":"Mackman","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00199.2020","article-title":"Heparin as a therapy for COVID-19: current evidence and future possibilities","volume":"319","author":"Hippensteel","year":"2020","journal-title":"American Journal of Physiology-lung Cellular And Molecular Physiology"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.2715","article-title":"Aspirin therapy on prophylactic anticoagulation for patients hospitalized with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry","volume":"11","author":"Santoro","year":"2022","journal-title":"Journal of the American Heart Association"},{"key":"B170","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ejh.13638","article-title":"White blood count, D-dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID-19 patients: The French multicenter CLOTVID retrospective study","volume":"107","author":"Galland","year":"2021","journal-title":"Eur J Haematol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20220016","article-title":"A central role for amyloid fibrin microclots in long COVID\/PASC: origins and therapeutic implications","volume":"479","author":"Kell","year":"2022","journal-title":"Biochem J"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07873-4","article-title":"Fibrin drives thromboinflammation and neuropathology in COVID-19","volume":"633","author":"Ryu","year":"2024","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1593885\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:33:31Z","timestamp":1754026411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1593885\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":172,"alternative-id":["10.3389\/fimmu.2025.1593885"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1593885","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"1593885"}}